|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online August 9, 2006
doi: 10.1242/10.1242/jcs.03061
Research Article |
1 Department of Biological Sciences, 14 Science Drive 4, Faculty of Science, National University of Singapore, Singapore 117543, Republic of Singapore
2 Department of Anatomy, Yong Loo Lin School of Medicine, 4 Medical Drive, National University of Singapore, Singapore 117597, Republic of Singapore
* Author for correspondence (e-mail: dbslowbc{at}nus.edu.sg)
Accepted 22 May 2006
 |
Summary |
|---|
 Top Summary IntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
Key words: BNIP-H/Caytaxin, Glutaminase, Cerebellum, Glutamate, Ataxia, Dystonia
|
Introduction |
|---|
|
TopSummaryIntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
). Mutations in the ATCAY gene on human chromosome 19 are linked to Cayman ataxia, but its function and mechanism of regulation remains unknown (Bomar et al., 2003). The gene is exclusively expressed in adult and embryonic neural tissues (Bomar et al., 2003) and the cDNA, first isolated in our laboratory (GenBank accession number AY220297), encodes the protein BNIP-H or Caytaxin. BNIP-H (for BNIP-2 homology) shares 52% amino acid sequence identity (69% similarity) with BNIP-2, originally identified as a partner for the anti-apoptotic proteins Bcl-2 and the adenovirus E1B 19-kDa protein (Boyd et al., 1994). We subsequently showed that it contains a novel homophilic and heterophilic protein-protein interaction domain known as the BNIP-2 and Cdc42GAP homology (BCH) domain that also targets the small GTPase, Cdc42 (Low et al., 2000a; Low et al., 2000b). Transient expression of BNIP-2 led to Cdc42-dependent cell dynamics such as cell elongation and membrane protrusions (Zhou et al., 2005a) whereas another homologue, BNIP-S
induces cell rounding and apoptosis through its intact BCH domain (Zhou et al., 2002) by displacing p50RhoGAP and facilitating RhoA activation by directly binding to them by unique motifs (Zhou et al., 2005b). The importance of the BCH domain was further exemplified by BPGAP1, a novel Rho GTPase-activating protein, that uses its BCH domain in concert with the adjacent proline-rich region to promote cell migration (Lua and Low, 2004) and Ras-MAPK signalling (Lua and Low, 2005). Interestingly, the two types of BNIP-H mutation found to be associated with Cayman ataxia were predicted to cause an amino acid change at the highly conserved position 301 (Ser to Arg) of the C-terminal BCH domain or a truncation of the BCH domain, respectively (Bomar et al., 2003). More recently, BNIP-H deficiency in rats was also found to cause generalised dystonia (Xiao and LeDoux, 2005), a neurological movement disorder characterised by sustained muscle contractions producing abnormal movements or postures. The deficiency was found to be caused by a 3' long terminal repeat portion of an intracisternal A particle element inserted into exon 1 of Atcay (Xiao and LeDoux, 2005). In another study, BNIP-H was found to be polyubiquitylated by the ubiquitin E3 ligase CHIP (C-terminus of Hsc70-interacting protein) in vitro, suggesting that BNIP-H degradation could be triggered by CHIP (Grelle et al., 2005). These discoveries and its exclusive expression in neural tissues imply that BNIP-H is likely to play important role(s) for the correct function and/or development of the human central nervous system.
Glutamate is the most abundant excitatory neurotransmitter in the human brain. At the same time, it is the precursor for the inhibitory neurotransmitter 
-aminobutyric acid (GABA) (Petroff, 2002). The synthesis of the neurotransmitter glutamate can be catalysed by phosphate-activated glutaminase (PAG), a mitochondrial enzyme converting glutamine to stoichiometric amounts of glutamate and ammonia (Kvamme et al., 2000). Four isoforms of PAG have been described: Kidney-type glutaminase (KGA) is highly expressed in the heart, kidney, intestine, foetal liver and brain, whereas its splicing isoforms, glutaminase C (GAC) and M (GAM), are expressed in tissues other than the brain (Curthoys and Watford, 1995; Elgadi et al., 1999). Liver-type glutaminase (LGA) is synthesised from a different gene (Aledo et al., 2000), and is expressed in postnatal liver, pancreas and brain (Aledo et al., 2000; Gomez-Fabre et al., 2000; Smith and Watford, 1990). Interestingly, brain LGA is localised to the nucleus (Olalla et al., 2002). Active KGA is a heterotetramer consisting of three 66 kDa subunits and one 68 kDa subunit. Both subunits are generated from a single 74 kDa precursor via a 72 kDa intermediate (Perera et al., 1990; Shapiro et al., 1991). PAG plays an important role in the glutamine-glutamate cycle between neurons and glia (Hassel et al., 1997; Hertz et al., 1999; Magistretti et al., 1999): During synaptic transmission, glutamate is released into the synaptic cleft. To avoid continuous activation of glutamate receptors, it is removed from the extracellular space and transported into glia, where glutamate is converted into glutamine. Glutamine is then released and transported back into neurons, where it is a substrate for PAG to replenish the released glutamate stores. Besides mediating synaptic transmission, high concentrations of extracellular glutamate could cause neuronal cell death by prolonged activation of glutamate receptors, a process referred to as excitotoxicity (Coyle and Puttfarcken, 1993; Atlante et al., 2001). Excitotoxicity contributes to neuronal damage in conditions such as cardiac arrest, stroke and seizures (Rothman and Olney, 1987; Choi and Rothman, 1990; Meldrum and Garthwaite, 1990; Muir and Lees, 1995). Recently, KGA was shown to be involved in an increased production of extracellular glutamate following neuronal death (Newcomb et al., 1997). In two other studies, elevated PAG expression and activity were linked to schizophrenia, supporting the glutamate hypothesis that dysregulation of glutamatergic neurotransmission contributes to schizophrenia (Gluck et al., 2002; Bruneau et al., 2005). Furthermore, Choudary et al. (Choudary et al., 2005) had suggested that changes in the cortical glutamatergic and GABAergic signal transmission could play an important role in depression.
Here, we describe the identification of KGA as a binding partner for BNIP-H in the brain. We show that BNIP-H regulates the spatial distribution and activity of KGA. To our knowledge, this is the first report on the physical interaction and regulation of a neurotransmitter-producing enzyme by a brain-specific protein, thus providing a possible molecular basis for the aetiology of Cayman ataxia and generalised dystonia, and possibly other related neurological disorders. The significance of this is discussed.
|
Results |
|---|
|
TopSummaryIntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
|
|
To delineate the reciprocal binding site(s) on KGA, various deletion constructs of FLAG-tagged KGA were co-expressed with HA-BNIP-H and tested for their binding inside the cells (Fig. 2D). Unlike the enzymatic domain of KGA (Region B), the flanking regions A and C were not involved in the binding to BNIP-H at all. To pinpoint more precise interaction sites, region B was further sub-divided and expressed as discrete subregions of B1, B2, B3 or their composites (B12 or B23). Our results clearly showed that Region B2 (aa 269-408) and Region B3 (aa 402-547) of the enzymatic domain of KGA were crucial for its interaction with BNIP-H (Fig. 2D). Finally, to determine whether BNIP-H-KGA interaction was primarily mediated through their direct binding and not by third party protein(s), FLAG-tagged KGA that harboured the BNIP-H binding region was produced by in vitro transcription and translation (Fig. 2E, lane 5), and then subjected to precipitation assays with purified GST-BNIP-H, GST-BNIP-2 or GST-BNIP-S fusion proteins. Western blot analysis showed that only the GST-BNIP-H bound to FLAG-tagged KGA (Fig. 2E, lane 3), but no binding was observed for GST-BNIP-2 or GST-BNIP-S (Fig. 2E, lane 1 and 2, respectively). A control western blot did not show nonspecific binding of FLAG antibody to the GST fusion proteins (data not shown). Taken together, these results confirm the identification of KGA as a novel and specific binding partner of BNIP-H, the brain-specific member of the BNIP-2 family proteins, thus highlighting their possible functional relevance in brain development or neurophysiology.
BNIP-H is enriched in the hippocampus and cerebellum, and its expression is activated in differentiating neurons
To shed light on the possible physiological roles of BNIP-H, we next determined the expression profiles of BNIP-H protein in mouse tissues and different regions of the brain. The BNIP-H antibody recognised a specific protein at around 60 kDa in the brain lysate but not in other tissues (Fig. 3A). This result confirmed the restricted neural distribution of BNIP-H mRNA (Bomar et al., 2003; Xiao and LeDoux, 2005). More significantly, this antibody allowed us to detect endogenous BNIP-H expression in different domains of the brain as performed by immunohistochemistry (IHC) with mouse brain sections (Fig. 3). BNIP-H expression was observed in major parts of the brain, including the cortex (Fig. 3B) but was more enriched in the hippocampus (Fig. 3B), cerebellar cortex (Fig. 3C), deep cerebellar nuclei (Fig. 3D) and pontine nuclei (Fig. 3E). The results are in agreement with previous studies where these brain structures (except for the deep cerebellar nuclei) were intensively labelled either in ISH experiments targeting the glutaminase mRNA (as for the hippocampus) (Najlerahim et al., 1990) or with a monoclonal antibody against glutaminase (as for the cerebellar cortex and the pontine nuclei) (Kaneko et al., 1987). Interestingly, the granule cell layer of the cerebellar cortex showed a staining pattern of small clusters of grains suggesting a possible BNIP-H localisation at the axon terminals (Fig. 3C). The staining pattern also shows striking similarity to that of glutaminase in rat brain slices (Kaneko et al., 1987). The CA3 of the hippocampus presented dot-like staining, indicating that BNIP-H is localised in the neuropil and synapses. No cell bodies were recognisable (Fig. 3B). Besides a fine punctate staining pattern in the deep cerebellar nuclei and pontine nuclei, cell bodies within these regions were intensively labelled with the BNIP-H antibody (Fig. 3D,E). To further investigate the possible role of BNIP-H in neuronal function, we used the embryonic carcinoma cell line P19 to further show that BNIP-H was expressed in neurons. These P19 cells when treated with retinoic acid could differentiate into neurons and glial cells (MacPherson and McBurney, 1995). BNIP-H was not detected in undifferentiated P19 cells but was expressed after nine days of differentiation as shown by western blotting (Fig. 4A). By contrast, glutaminase immunoreactivity was detected in cell lysates of both undifferentiated as well as differentiated P19 cells (Fig. 4A). Several bands were detected with a polyclonal antiserum, suggesting the presence of constitutively expressed multiple isoforms. The KGA form that migrated at the expected size is indicated by the arrow (Fig. 4A). Immunofluorescence studies further showed the colocalisation of BNIP-H and glutaminase with the neuron-specific marker neurofilament-160 within the cell bodies and neurites (Fig. 4B,C). These results further support the importance of BNIP-H in carrying out specific function(s) in differentiating neurons. Based on the labelling pattern and intensity, our results strongly suggest that BNIP-H could play an important role in the hippocampus and the cerebellum, possibly in the process of neurotransmission at synapses.
|
|
To correlate the protein expression profiles of BNIP-H with its gene expression, we conducted parallel in situ hybridisation (ISH) histochemistry against its mRNA in rat brain slices. Our results showed a similar staining pattern to that observed with IHC (Fig. 5A,B). Furthermore, the expression of BNIP-H in the spinal cord was detected (Fig. 5C). Interestingly, some differences were noted: CA1, CA2 and the dentate gyrus of the hippocampus were intensely labelled by ISH histochemistry but were not stained by IHC. The Purkinje cell layer was also strongly labelled by ISH histochemistry (Fig. 5B inset), but the labelling was relatively weak with BNIP-H antibody. This might be due to the fact that BNIP-H expression could be under control at both transcriptional and translational levels in specific regions of the brain. Parallel experiments with a probe against juxtanodin mRNA revealed a distinct staining pattern (Zhang et al., 2005), indicating stringent hybridisation conditions.
|
|
BNIP-H reduces the steady-state levels of glutamate by inhibiting KGA enzyme activity
KGA is a phosphate-dependent glutaminase possibly responsible also for the production of the neurotransmitter glutamate. Our results suggest that spatial regulation of KGA by BNIP-H might influence the steady-state levels of glutamate. However, as a result of low transfection efficiency of PC12 and the inability to generate stable cells with singly or doubly transfected BNIP-H and/or KGA in these cells, we opted for 293T epithelial cells that were efficiently transfected for optimal biochemical assays. Aliquots of lysates from single- or double-transfected cells were analysed for KGA expression by western blotting. The rest of the lysate was deproteinated and the total amount of glutamate intracellularly as well as in the medium was determined enzymatically (see Materials and Methods). Values were corrected for the endogenous amount of glutamate in mock-transfected samples (Fig. 7A). Cells expressing KGA showed a marked increase in the total glutamate level, either intracellularly (42.0±2.3 nmol, mean ± s.d., P<0.0001) or as released into the medium (130.6±20.8 nmol, P<0.0001), when compared with the mock-transfected samples. This result showed that exogenously expressed KGA is active inside the cells. By contrast, expression of BNIP-H had no significant effect on the basal glutamate levels. However, when compared with those elicited by KGA alone, co-expression of KGA with BNIP-H led to a significant reduction in the glutamate levels either intracellularly (8.0±2.0 nmol, P<0.0001) or in the medium (71.6±45.9 nmol, P=0.02). By contrast and as a control, co-expressed EF1A1 that did not interact or redistribute KGA as observed before (Fig. 2C and data not shown) had no effect on the production of glutamate elicited by KGA (42.9±3.4 nmol, P=0.59; for the intracellular level and 126.8±9.8 nmol, P=0.84; for the medium). These results strongly suggest that BNIP-H either directly or indirectly downregulates the steady-state levels of glutamate. To show that BNIP-H inhibited glutaminase activity through its binding to KGA, we performed an enzyme assay by reconstituting the BNIP-H-KGA complex in vitro. We used bacterially expressed and purified GST-fusion of the full-length (FL) BNIP-H and incubated it with lysates from 293T cells that overexpressed FLAG-tagged KGA. As controls, GST-BNIP-H (aa 1-190), which does not bind KGA, or the GST alone, was used. After pre-incubation of lysate with equal amounts of these GST constructs, glutamine was added to the sample for the times indicated and the total amount of glutamate was determined as described in the Materials and Methods. Fig. 7B shows that the rate of glutamate production was greatly reduced in the presence of GST-BNIP-H FL but not with GST-BNIP-H (aa 1-190). Calculation of the close-linear rates at 5 minutes indicated that the rate of glutamate production in the presence of GST-BNIP-H FL was only 14±0.1% (P=0.005) of that in the sample with GST alone or with the GST-BNIP-H (aa 1-190). All these results indicate that BNIP-H downregulates the steady-state levels of glutamate in the cells by directly binding and inhibiting the glutaminase activity of KGA. This could in turn modulate the homeostasis of glutamate necessary for proper neuronal functions. The significance of this is discussed.
|
|
Discussion |
|---|
|
TopSummaryIntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
) showed that the upregulation of glutaminase expression is parallel to the formation of neurites and synapses of cerebellar granule cells between days three and ten in vitro. Several groups have shown the localisation of KGA in axon terminals (Aoki et al., 1991; Laake et al., 1999) where its function is believed to be the synthesis of the neurotransmitter glutamate. Therefore, the absence of KGA or lowering of its enzymatic activity in synapses could lead to reduced levels of glutamate in the axon terminals. In Drosophila, increased or reduced levels of glutamate by genetic manipulations have recently been shown to inversely affect the postsynaptic receptor field size (Featherstone et al., 2002). Furthermore, pharmacological interference blocking the degradation of -aminobutyric acid (GABA) caused an increase in the synaptic efficacy (Engel et al., 2001). It is therefore possible that in the absence or malfunction of BNIP-H, the misdisposition of KGA would result in a reduction in local concentrations of glutamate in the axon terminals. Likewise, this could result in an elevated glutaminase activity that leads to an overall rise in glutamate levels, which can affect the efficacy of neurotransmission.
It had previously been shown that experimentally enhanced extracellular glutamate levels led to cell death of mature cortical neurons in cell culture (Choi et al., 1987). Furthermore, it was shown that knocking down glial glutamate transporters important for glutamate clearance could also result in elevated extracellular glutamate levels and neurodegeneration characteristic of neurotoxicity (Rothstein et al., 1996). Consistently, changes in the gene expression of a key glutamate-metabolising enzyme, the L-glutamate-ammonia ligase and glutamate transporters could also modulate the levels of extracellular glutamate. This could in turn lead to the neurotoxicity associated with depression (Choudary et al., 2005). In patients suffering from Cayman ataxia an apparent cerebellar hypoplasia was reported (Bomar et al., 2003), further implicating that the absence of functional BNIP-H, presumably leading to an accumulation of glutamate in the cell bodies of neurons, could lead to abnormal neuronal growth and/or neurotoxicity induced by glutamate in the extracellular space.
In addition to human Cayman ataxia, various forms of mutation in the BNIP-H gene have now been identified in three mice mutants (jittery, hesitant and sidewinder) and in one rat mutant model for dystonia (Bomar et al., 2003; Xiao and LeDoux, 2005). However, unlike human Cayman ataxia, the mutations in the dystonic rat model and those in the jittery and sidewinder mouse mutants are generally lethal as they probably cause more drastic changes in BNIP-H structure and quantity than the mutations observed in humans (Xiao and LeDoux, 2005). Interestingly, cerebellectomy could partially rescue the phenotype and prolong the lifespan of the dystonic rat (LeDoux et al., 1993), supporting the notion that BNIP-H does play an important role in the correct functioning of the cerebellum for movement control. Indeed, induction of dystonia upon injection of low doses of kainic acid into cerebellar vermis of mice depends on glutamatergic activation (Pizoli et al., 2002). Furthermore, the authors suggested that the cerebellar cortex plays a crucial role in this model of dystonia (Pizoli et al., 2002). These findings are consistent with our data of strong BNIP-H expression in the cerebellar cortex as detected by in situ hybridisation and immunohistochemistry (Figs 3 and 5). All these results, related to either neurotransmission or neurotoxicity, seem to point to a plausible circuitry network of control between the glutaminase, glutamate and BNIP-H. Dysregulation of such checkpoint, such as the loss of BNIP-H, could underlie the molecular basis and the etiology of cerebellar ataxia, dystonia, and possibly other related neurological disorders.
Finding the precise mode of physical interaction between BNIP-H and glutaminase is important as it allows better understanding on their functional control. We showed that such interaction is mediated by their direct binding in a constitutive manner. Our current work also shows that it involves at least two regions within the BCH domain of BNIP-H - Site I (aa 191-235) and Site II (aa 288-331) - targeting the more distal parts of the enzymatic moiety of KGA (aa 269-547). Interestingly, Site II of the BCH domain encompasses the homozygous Ser301Arg mutation associated with Cayman ataxia (Bomar et al., 2003). However, as expected from the nature of dual-site interaction, this single-point mutation alone does not affect the binding of BNIP-H to KGA (our unpublished data). On the other hand, the splicing mutation in intron 9 of the BNIP-H gene is predicted to cause a truncation of the conserved BCH domain (Bomar et al., 2003). It remains unclear if indeed this truncated form is ever expressed in patients suffering from Cayman ataxia. Further deletion studies within these regions failed to conveniently pinpoint any specific or subtle motifs, indicating that the nature of their interaction is likely to be complex. The answer to this should await high-resolution structural determination. Nonetheless, our current findings on the absolute importance of a functional BCH domain in binding and regulating KGA activity, hence glutamate homeostasis, seem to be a plausible model for further investigation on the molecular basis for this and other related neurological disorders.
In addition, our binding studies have further exemplified the repertoire of BCH domain as a dynamic protein-protein interaction device. It is now evident that different members use specific motifs to mediate their homophilic or heterophilic interactions (Low et al., 1999; Low et al., 2000b; Zhou et al., 2002; Shang et al., 2003), and also engaging Rho subfamily small GTPases to elicit cell protrusions (e.g. BNIP-2 and BPGAP1) (Zhou et al., 2005a; Shang et al., 2003) or cell rounding during apoptosis (e.g. BNIP-S) (Zhou et al., 2002; Zhou et al., 2005b). It has been postulated that part of the BCH domain of BNIP-H that weakly resembles the CRAL/TRIO domain (a domain that binds small lipophilic molecules) might be important for targeting specific ligand for its normal function (Bomar et al., 2003). However, this hypothesis has never been tested. Our data on the other hand revealed the unexpected role of the BCH domain in promoting intracellular trafficking and regulating the activity of a key enzyme that is important for neuronal function. Whether or not this property of trafficking is linked to its ability of targeting specific small GTPases, its homophilic or heterophilic binding or lipid binding remains to be seen. Currently, our data show that BNIP-H, unlike BNIP-2 and BNIP-S, does not interact with members of the Rho subfamily GTPases such as Cdc42, RhoA and Rac1 (our unpublished data), raising the possibility that other types of GTPases might be uniquely involved in the BNIP-H signalling pathway. A more detailed investigation is currently underway in our laboratory to probe the mechanistic control of such trafficking, in particularly the possible involvement of cytoskeletal components.
At present, we also show that retinoic-acid-induced differentiation of P19 cells was accompanied by the activation of BNIP-H gene expression in developing and differentiating neurons, suggesting that BNIP-H expression is also regulated at cellular level during the early stages of brain development. This is consistent with the BNIP-H mRNA being developmentally regulated in the hippocampus and cerebellum (Xiao and LeDoux, 2005). Interestingly, the Purkinje cell layer known for its GABAergic neurons appeared to express BNIP-H although glutaminase is known to be absent in Purkinje cells of the adult rodent brain. This implies that BNIP-H could have functions other than just the relocalisation of glutaminase in certain cellular systems or developmental stages.
Taken together, we have identified and confirmed KGA as a novel target of BNIP-H in the brain where their interaction could play an important role in reducing the steady state levels of glutamate in the cells. Based on the biochemistry of glutamate and the pathophysiological outcomes arising from the loss of BNIP-H in human and mice or rat models of ataxia and dystonia as discussed above, our findings could present a novel paradigm for regulating the homeostasis of glutamate synthesis important for proper neurotransmission and/or neuronal cell growth. The immediate challenge now is to determine both the in vivo levels of glutaminase activity and glutamate in the neurons of the mouse or rat models with defective BNIP-H function, as well as their effects on neurotransmission and neurotoxicity. Following this, they should be subjected to genetic or biochemical means of lowering the activity of glutaminase (e.g. by conditional knockout of KGA or inhibitory peptide from BNIP-H) or to `dampen' the excessive glutamate from uncontrolled glutamatergic activation or neuroexcitotoxicity.
|
Materials and Methods |
|---|
|
TopSummaryIntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
). The extracted peptides were analysed on a matrix-assisted laser desorption/ionisation mass spectrometer equipped with a time-of-flight analyser (MALDI-TOF; Voyager STR BioSpectrometry workstation, Applied System). The obtained mass fingerprints were then used to perform a MS-Fit search on NCBI databases to identify the protein.
Plasmid construction
The FLAG and HA expression vectors were from Ed Manser (Institute for Molecular and Cell Biology, Singapore). The KGA cDNA was a generous gift from Norman P. Curthoys (Colorado State University, Fort Collins; GenBank accession number AF327434) (Holcomb et al., 2000). KGA full-length cDNA or various fragments were generated through polymerase chain reaction (PCR) with appropriate primers containing either a BamHI or XhoI restriction site for cloning into the FLAG- and HA-pXJ40 expression vectors. Full-length BNIP-H or its fragments were generated in the same way using BamHI and XhoI restriction sites and cloned into FLAG- and HA-pXJ40 expression vectors. Constructs were verified through sequencing and propagated in E. coli strains XL1-blue and DH5.
Generation and purification of BNIP-H antibodies
Polyclonal antibodies against a fusion protein consisting of GST and full-length human BNIP-H were generated in New Zealand white rabbits by subcutaneous injections of approximately 1 mg of antigen. For the first injection the antigen was mixed with Freund's complete adjuvant, subsequently incomplete adjuvant (both from Sigma) was used. After three booster injections every 3 weeks, blood was collected and serum was prepared. Anti-BNIP-H antibodies were affinity purified with a fusion protein consisting of thioredoxin and full-length human BNIP-H expressed in E. coli BL21 and transferred onto a PVDF membrane. Anti-BNIP-H antibodies were eluted with 100 mM glycine (pH 2.0); the solution was neutralised with 1/10 volume 1.5 M Tris-HCl (pH 8.0).
Cell culture and transfection
Human 293T cells were grown in RPMI 1640 medium (Hyclone) supplemented with 10% (v/v) fetal bovine serum, 10 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (all from Hyclone). Cells at 60-80% confluence in six-well plates were transfected with 1-1.75 µg plasmid using Fugene 6 cationic lipid (Roche), according to the manufacturer's instructions. PC12 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 4500 mg glucose, 10 mM HEPES, 5% fetal bovine serum (all from Hyclone) and 10% horse serum (Gibco). PC12 cells on poly-D-lysine (Sigma) coated surfaces were transfected with Lipofectamine 2000 Reagent (Invitrogen), according to the manufacturer's instructions. Differentiation was induced with 40 ng/ml nerve growth factor (NGF) in the presence of 0.5% serum. P19 cells were cultured in alpha-modified Minimal Essential Medium supplemented with 7.5% bovine serum (both from Gibco) and 2.5% fetal bovine serum (Hyclone) and differentiated essentially as described (Jones-Villeneuve et al., 1982; MacPherson and McBurney, 1995). Briefly, neuronal differentiation was induced with 0.5 µM retinoic acid (RA) in serum-supplemented medium for 4-5 days in bacterial grade cell culture dishes. Cell aggregates were than plated into cell culture dishes containing normal growth medium without RA and further differentiated for 5-6 days. Cells were treated with cytosine arabinoside (5 µg/ml) for several days to inhibit the growth of non-neuronal cells. For confocal immunofluorescence studies, P19 cells were grown on gelatin-coated coverslips.
Co-immunoprecipitation (CoIP), direct binding assay
Transfected cells were lysed in 200 µl lysis buffer (50 mM Tris-HCl pH 7.3, 150 mM NaCl, 0.75 mM EDTA, 1% sodium deoxycholate, 1% Triton-X-100, 0.2% sodium fluoride, 25 mM glycerol 2-phosphate, 5 mM sodium orthovanadate and a mixture of protease inhibitors) per well. Aliquots were either directly analysed by western blotting or were used for protein-binding studies. For use in CoIP, lysates were incubated with anti-FLAG antibody conjugated to agarose beads (Sigma) at 4°C overnight. The beads were extensively washed with lysis buffer and analysed by western blotting with monoclonal and polyclonal anti-FLAG antibodies (Sigma) and anti-HA antibody (Zymed). To show direct binding, purified GST fusion proteins (5 µg) of BNIP-H, BNIP-2 and BNIP-S immobilised on glutathione-Sepharose (Amersham Biosciences) were incubated with FLAG-tagged KGA (aa 134-669) produced by in vitro transcription and translation (Promega) at 4°C overnight. After washing with lysis buffer, samples were analysed by western blotting with an anti-FLAG antibody (Sigma). For CoIP of endogenous proteins, mouse brain was homogenised in lysis buffer with a Dounce tissue grinder (Wheaton). After centrifugation, the lysate was precleared with protein A/G-agarose (Santa Cruz Biotechnology) for 5 hours at 4°C. Anti-BNIP-H antibody or pre-immune serum was added to the lysate and samples were incubated at 4°C overnight. Immunocomplexes were captured by adding protein A/G-agarose for 3.5 hours. After washing with lysis buffer, samples were analysed by western blotting with various antibodies. The polyclonal glutaminase antiserum (Curthoys et al., 1976) was a generous gift from Norman P. Curthoys (Colorado State University, Fort Collins).
In situ hybridisation (ISH)
Adult rats were deeply anesthetised and transcardially perfused with saline followed by 3% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The brain and the cervical spinal cord were dissected, postfixed, and sectioned into cryostat sections. Digoxigenin-labelled riboprobes were synthesised by in vitro transcription with rat BNIP-H cDNA (nucleotides 334-1452, GenBank accession number XM_343154.1) inserted into pGEM-T Easy (Promega) as a template. ISH histochemistry (probe concentration of 0.2 µg/ml) followed a protocol previously described (Liang et al., 2000).
Immunohistochemistry (IHC)
IHC was carried out with the Vectastain Elite ABC-Kit (Vector Laboratories) according to the manufacturer's instructions. Briefly, paraffin-embedded mouse brain sections were deparaffinised and hydrated through xylenes and a graded alcohol series, respectively. After rinsing with water, sections were cooked in 0.1 M citric acid (pH 6.1) for 10 minutes and allowed to cool down to room temperature. Sections were washed with PBS and placed in 0.3% H2O2 to quench endogenous peroxidase activity, and washed again. Sections were incubated with normal blocking serum for 1 hour and then with anti-BNIP-H antibody overnight. After washing, sections were incubated for 1 hour with biotinylated secondary antibody followed by incubation with a preformed complex of avidin and biotinylated peroxidase. Sections were incubated in peroxidase substrate solution (diaminobenzidine tetrahydrochloride, DAB) until desired stain intensity developed, rinsed with water, cleared and mounted. Pictures were taken with an AxioCam MRc5 camera fixed on an Axioskop 2 mot plus microscope (both from Zeiss) and Axiovision 4 software (Zeiss).
Immunofluorescence
PC12 cells grown on sterilised poly-D-lysine-coated glass coverslips were washed twice with PBS and fixed with 3.7% formaldehyde for 15 minutes at 37°C. Fixed cells were washed twice with PBS and permeabilised with 0.2% Triton X-100 (BioRad) in PBS for 15 minutes at room temperature. Blocking was carried out with 2% bovine serum albumin and 7% fetal bovine serum in PBS for 30 to 60 minutes at room temperature. Cells were incubated with anti-FLAG (Sigma) and anti-HA (Zymed) antibodies in blocking solution. Samples were washed three times with 0.1% Triton X-100-containing PBS before incubation with Rhodamine-conjugated goat anti-mouse IgG (Chemicon), Fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories), Alexa Fluor 488-conjugated donkey anti-mouse IgG, Alexa Fluor 594-conjugated goat anti-rabbit IgG or Pacific Blue-conjugated goat anti rabbit IgG (all Molecular Probes). Mitochondria were stained with MitoTracker Orange CMTMRos (Molecular Probes) according to manufacturer's instructions. P19 cells were processed the same way except that cells were postfixed with 3.7% formaldehyde at 4°C overnight. The neurofilament-160 antibody was from Sigma. Pictures were taken with a confocal microscope (Zeiss).
Glutamate and glutaminase assay
The total amount of glutamate in the cell lysate and cell culture medium was determined enzymatically essentially as described (Lund, 1986). Transfected cells were washed twice with PBS and harvested with cold lysis buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 10 mM MgCl2, 5 mM EDTA, 10% glycerol, 1% Triton X-100, 5 mM sodium orthovanadate, 5 mM glycerol 2-phosphate and a mixture of protease inhibitors). After centrifugation, an aliquot of the lysate was analysed by western blotting for equal expression of FLAG-KGA in double transfected cells and expression of HA-BNIP-H and FLAG-EF1A1, respectively. The rest of the lysate was deproteinated with 1/20 volume of 100% trichloroacetic acid (TCA) and centrifuged for 5 minutes. The supernatant was immediately neutralised with potassium hydroxide. 20 µl of the deproteinated lysate in a final volume of 200 µl were incubated with 80 mM Tris-acetate pH 9.4, 200 mM hydrazine, 0.25 mM ADP, 2 mM NAD and 2.2 U glutamate dehydrogenase for 40 minutes at room temperature. The absorbance at 340 nm was measured with an ELISA reader (SpectraMax 340, Molecular Devices) to evaluate the conversion of NAD+ to NADH, and thus the amount of oxidised glutamate. The measurement was repeated after 5 minutes to confirm completeness of enzymatic conversion. The glutamate amount in the medium was determined the same way but without trichloroacetic acid precipitation. Analysis of variance was carried out separately for each group of values (lysate, medium, total, n=3) with the Newman-Keuls multiple range test and was calculated with StatsDirect statistical software. For the glutaminase enzyme assay GST-tagged BNIP-H FL, GST-BNIP-H (aa 1-190) and GST were exogenously expressed in E. coli, purified and eluted from glutathione-Sepharose beads with 10 mM glutathione. Lysates from 293T cells containing overexpressed FLAG-tagged KGA were separately incubated with equal amounts (5 µg) of GST fusion proteins or GST for 1 hour at room temperature. After incubation 20 mM glutamine was added to the sample for 0, 2, 5 and 10 minutes. Samples were than TCA precipitated and the total amount of glutamate was determined as described above. The results presented are from three independent experiments. Statistical significant difference was analyzed with Student's t-test (paired, two-tailed).
|
Acknowledgments |
|---|
|
References |
|---|
|
TopSummaryIntroductionResultsDiscussionMaterials and MethodsReferences |
|---|
Aledo, J. C., Gomez-Fabre, P. M., Olalla, L. and Marquez, J. (2000). Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm. Genome 11, 1107-1110.[CrossRef][Medline]
Aoki, C., Kaneko, T., Starr, A. and Pickel, V. M. (1991). Identification of mitochondrial and non-mitochondrial glutaminase within select neurons and glia of rat forebrain by electron microscopic immunocytochemistry. J. Neurosci. Res. 28, 531-548.[CrossRef][Medline]
Atlante, A., Calissano, P., Bobba, A., Giannattasio, S., Marra, E. and Passarella, S. (2001). Glutamate neurotoxicity, oxidative stress and mitochondria. FEBS Lett. 497, 1-5.[CrossRef][Medline]
Bomar, J. M., Benke, P. J., Slattery, E. L., Puttagunta, R., Taylor, L. P., Seong, E., Nystuen, A., Chen, W., Albin, R. L., Patel, P. D. et al. (2003). Mutations in a novel gene encoding a CRAL-TRIO domain cause human Cayman ataxia and ataxia/dystonia in the jittery mouse. Nat. Genet. 35, 264-269.[CrossRef][Medline]
Boyd, J. M., Malstrom, S., Subramanian, T., Venkatesh, L. K., Schaeper, U., Elangovan, B., D'Sa-Eipper, C. and Chinnadurai, G. (1994). Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. Cell 79, 341-351.[CrossRef][Medline]
Bruneau, E. G., McCullumsmith, R. E., Haroutunian, V., Davis, K. L. and Meador-Woodruff, J. H. (2005). Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr. Res. 75, 27-34.[CrossRef][Medline]
Choi, D. W. and Rothman, S. M. (1990). The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13, 171-182.[CrossRef][Medline]
Choi, D. W., Maulucci-Gedde, M. and Kriegstein, A. R. (1987). Glutamate neurotoxicity in cortical cell culture. J. Neurosci. 7, 357-368.[Abstract]
Choudary, P. V., Molnar, M., Evans, S. J., Tomita. H., Li, J. Z., Vawter, M. P., Myers, R. M., Bunney, W. E., Jr, Akil, H., Watson, S. J. et al. (2005). Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. USA 102, 15653-15658.
Coyle, J. T. and Puttfarcken, P. (1993). Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689-695.
Curthoys, N. P. and Watford, M. (1995). Regulation of glutaminase activity and glutamine metabolism. Annu. Rev. Nutr. 15, 133-159.[CrossRef][Medline]
Curthoys, N. P., Kuhlenschmidt, T., Godfrey, S. S. and Weiss, R. F. (1976). Phosphate-dependent glutaminase from rat kidney. Cause of increased activity in response to acidosis and identity with glutaminase from other tissues. Arch. Biochem. Biophys. 172, 162-167.[CrossRef][Medline]
Elgadi, K. M., Meguid, R. A., Qian, M., Souba, W. W. and Abcouwer, S. F. (1999). Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol. Genomics 1, 51-62.
Engel, D., Pahner, I., Schulze, K., Frahm, C., Jarry, H., Ahnert-Hilger, G. and Draguhn, A. (2001). Plasticity of rat central inhibitory synapses through GABA metabolism. J. Physiol. 535, 2, 473-482.
Featherstone, D. E., Rushton, E. and Broadie, K. (2002). Developmental regulation of glutamate receptor field size by nonvesicular glutamate release. Nat. Neurosci. 5, 141-146.[CrossRef][Medline]
Gluck, M. R., Thomas, R. G., Davis, K. L. and Haroutunian, V. (2002). Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am. J. Psychiatry 159, 1165-1173.
Gomez-Fabre, P. M., Aledo, J. C., Del Castillo-Olivares, A., Alonso, F. J., Nunez De Castro, I., Campos, J. A. and Marquez, J. (2000). Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase. Biochem. J. 345, 365-375.
Grelle, G., Kostka, S., Otto, A., Kersten, B., Genser, K. F., Muller, E. C., Walter, S., Boddrich, A., Stelzl, U., Hanig, C. et al. (2005). Identification of VCP/p97, CHIP and amphiphysin II interaction partners using membrane-based human proteome arrays. Mol. Cell Proteomics 5, 234-244.
Hassel, B., Bachelard, H., Jones, P., Fonnum, F. and Sonnewald, U. (1997). Trafficking of amino acids between neurons and glia in vivo. Effects of inhibition of glial metabolism by fluoroacetate. J. Cereb. Blood Flow Metab. 17, 1230-1238.[CrossRef][Medline]
Hertz, L., Dringen, R., Schousboe, A. and Robinson, S. R. (1999). Astrocytes: glutamate producers for neurons. J. Neurosci. Res. 57, 417-428.[CrossRef][Medline]
Holcomb, T., Taylor, L., Trohkimoinen, J. and Curthoys, M. P. (2000). Isolation, characterization and expression of a human brain mitochondrial glutaminase cDNA. Brain Res. Mol. Brain Res. 76, 56-63.[Medline]
Jones-Villeneuve, E. M. V., McBurney, M. W., Rogers, K. A. and Kalnins, V. I. (1982). Retinoic acid induces embryonal carcinoma cells to differentiate into neurons and glial cells. J. Cell Biol. 94, 253-262.
Kaneko, T., Urade, Y., Watanabe, Y. and Mizuno, N. (1987). Production, characterization, and immunohistochemical application of monoclonal antibodies to glutaminase purified from rat brain. J. Neurosci. 7, 302-309.[Abstract]
Kvamme, E., Roberg, B. and Torgner, I. A. (2000). Phosphate-activated glutaminase and mitochondrial glutamine transport in the brain. Neurochem. Res. 25, 1407-1419.[CrossRef][Medline]
Laake, J. H., Takumi, Y., Eidet, J., Torgner, I. A., Roberg, B., Kvamme, E. and Ottersen, O. P. (1999). Postembedding immunogold labelling reveals subcellular localization and pathway-specific enrichment of phosphate activated glutaminase in rat cerebellum. Neuroscience 88, 1137-1151.[CrossRef][Medline]
LeDoux, M. S., Lorden, J. F. and Ervin, J. M. (1993). Cerebellectomy eliminates the motor syndrome of the genetically dystonic rat. Exp. Neurol. 120, 302-310.[CrossRef][Medline]
Liang, F., Hatanaka, Y., Saito, H., Yamamori, T. and Hashikawa, T. (2000). Differential expression of -aminobutyric acid type B receptor-1a and -1b mRNA variants in GABA and non-GABAergic neurons of the rat brain. J. Comp. Neurol. 416, 475-495.[CrossRef][Medline]
Low, B. C., Lim, Y. P., Lim, J., Wong, E. S. and Guy, G. R. (1999). Tyrosine phosphorylation of the Bcl-2-associated protein BNIP-2 by fibroblast growth factor receptor-1 prevents its binding to Cdc42GAP and Cdc42. J. Biol. Chem. 274, 33123-33130.
Low, B. C., Seow, K. T. and Guy, G. R. (2000a). Evidence for a novel Cdc42GAP domain at the carboxyl terminus of BNIP-2. J. Biol. Chem. 275, 14415-14422.
Low, B. C., Seow, K. T. and Guy, G. R. (2000b). The BNIP-2 and Cdc42GAP homology domain of BNIP-2 mediates its homophilic association and heterophilic interaction with Cdc42GAP. J. Biol. Chem. 275, 37742-37751.
Lua, L. B. and Low, B. C. (2004). BPGAP1 interacts with cortactin and facilitates its translocation to cell periphery for enhanced cell migration. Mol. Biol. Cell 6, 2873-2883.
Lua, L. B. and Low, B. C. (2005). Activation of EGF receptor endocytosis and ERK1/2 signaling by BPGAP1 requires direct interaction with EEN/endophilin II and a functional RhoGAP domain. J. Cell Sci. 118, 2707-2721.
Lund, P. (1986). L-Glutamine and L-Glutamate: UV-Method with glutaminase and glutamate dehydrogenase. In Methods of Enzymatic Analysis. Vol. 8 (ed. H. U. Bergmeyer), pp. 357-363, Weinheim: VCH Verlagsgesellschaft.
MacPherson, P. A. and McBurney, M. W. (1995). P19 embryonal carcinoma cells: a source of cultured neurons amenable to genetic manipulation. Methods 7, 238-252.[CrossRef]
Magistretti, P. J., Pellerin, L., Rothman, D. L. and Shulman, R. G. (1999). Energy on demand. Science 283, 496-497.
Meldrum, B. and Garthwaite, J. (1990). Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11, 379-387.[CrossRef][Medline]
Muir, K. W. and Lees, K. R. (1995). Clinical experience with excitatory amino acid antagonist drugs. Stroke 26, 503-513.
Najlerahim, A., Harrison, P. J., Barton, A. J., Heffernan, J. and Pearson, R. C. (1990). Distribution of messenger RNAs encoding the enzymes glutaminase, aspartate aminotransferase and glutamic acid decarboxylase in rat brain. Brain Res. Mol. Brain Res. 7, 317-333.[Medline]
Newcomb, R., Sun, X., Taylor, L., Curthoys, N. and Giffard, R. G. (1997). Increased production of extracellular glutamate by the mitochondrial glutaminase following neuronal death. J. Biol. Chem. 272, 11276-11282.
Nystuen, A., Benke, P. J., Merren, J., Stone, E. M. and Sheffield, V. C. (1996). A cerebellar ataxia locus identified by DNA pooling to search for linkage disequilibrium in an isolated population from the Cayman Islands. Hum. Mol. Genet. 5, 525-531.
Olalla, L., Gutierrez, A., Campos, J. A., Khan, Z. U., Alonso, F. J., Segura, J. A., Marquez, J. and Aledo, J. C. (2002). Nuclear localization of L-type glutaminase in mammalian brain. J. Biol. Chem. 277, 38939-38944.
Perera, S. Y., Chen, T. C. and Curthoys, N. P. (1990). Biosynthesis and processing of renal mitochondrial glutaminase in cultured proximal tubular epithelial cells and in isolated mitochondria. J. Biol. Chem. 265, 17764-17770.
Petroff, O. A. (2002). GABA and glutamate in the human brain. Neuroscientist 8, 562-573.[CrossRef][Medline]
Pizoli, C. E., Jinnah, H. A., Billingsley, M. L. and Hess, E. J. (2002). Abnormal cerebellar signalling induces dystonia in mice. J. Neurosci. 22, 7825-7833.
Rothman, S. M. and Olney, J. W. (1987). Excitotoxity and the NMDA receptor. Trends Neurosci. 10, 299-302.[CrossRef]
Rothstein, J. D., Dykes-Hoberg, M., Pardo, C. A., Bristol, L. A., Jin, L., Kuncl, R. W., Kanai, Y., Hediger, M. A., Wang, Y., Schielke, J. P. et al. (1996). Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675-686.[CrossRef][Medline]
Shang, X., Zhou, Y. T. and Low, B. C. (2003). Concerted regulation of cell dynamics by BNIP-2 and Cdc42GAP homology/Sec14p-like, proline-rich, and GTPase-activating protein domains of a novel Rho GTPase-activating protein, BPGAP1. J. Biol. Chem. 278, 45903-45914.
Shapiro, R. A., Farrell, L., Srinivasan, M. and Curthoys, N. P. (1991). Isolation, characterization, and in vitro expression of a cDNA that encodes the kidney isoenzyme of the mitochondrial glutaminase J. Biol. Chem. 266, 18792-18796.
Shevchenko, A., Wilm, M., Vorm, O. and Mann, M. (1996). Mas
